14. September 2017

The purpose of this study was to formulate compression coated tablets of mesalamine and prednisolone for colon specific delivery and evaluate their in vitro and in vivo performances.

09. July 2017

Mesalamine has been used for treatment of diseases like ulcerative colitis and chron's disease which affect the colonic lumen and require local drug action, rather than systemic effect.1 ; 2 Several research workers have worked on delayed release devices (with enteric coatings which can bypass the upper gastrointestinal tract) which can thereafter release the drug immediately or sustain drug release in the form of matrix tablets, capsules, pellets or multiparticulate systems.

09. August 2016

Abstract Direct delivery of sustained therapeutic levels of mesalamine (MS) via rectal systems to manage distal forms of ulcerative colitis was studied. The High molecular weight hydroxypropyl methylcellulose (HPMC K4M) polymer was combined with hydrophilic surfactants to control polymer hydration process allowing optimization of the mucoadhesive and controlled drug release properties for the rectal systems. Physical mixtures and granules of MS and HPMC K4M were prepared and in vitro...

10. July 2016

Abstract: The aim of the present study was to design a new pH–enzyme double-dependent mesalamine colon-specific delivery system. The drug release behaviors in vitro and pharmacokinetics and biodistribution in vivo were further evaluated. The mean particle diameters of mesalamine-coated microparticles were 312.2 μm. In vitro, a small amount of mesalamine was released in HCl at a pH of 1.2 and PBS medium at a pH of 7.4 for 5 hours, and 71% of the entrapped mesalamine was further released...

24. November 2015

Two well-known active agents, Mesalamine (MES) and Sucralfate (SUC), were investigated for possible utilisation as fixed-dose combination product. The anti-inflammatory action of MES in association with bioadhesiveness and mucosal healing properties of SUC were considered promising for the development of a new compound containing both molecules, aimed as an improved treatment of ulcerative colitis. More

10. July 2015

A new design for nanocomposite hydrogels based on cross-linked chitosan for the delivery of mesalamine is presented. To enhance drug loading in chitosan, the mineral montmorillonite was incorporated into the matrix. The exfoliated silica montmorillonite nanosheets form interactions with both chitosan and mesalamine, which affect the hydrogel’s drug release mechanism and swelling properties. More